Logo image of SNGX

SOLIGENIX INC (SNGX) Stock Price, Quote, News and Overview

NASDAQ:SNGX - Nasdaq - US8342236044 - Common Stock - Currency: USD

1.91  +0.1 (+5.52%)

SNGX Quote, Performance and Key Statistics

SOLIGENIX INC

NASDAQ:SNGX (5/27/2025, 8:00:02 PM)

1.91

+0.1 (+5.52%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High14.83
52 Week Low1.68
Market Cap6.23M
Shares3.26M
Float3.26M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-07 2025-08-07
IPO04-04 1994-04-04


SNGX short term performance overview.The bars show the price performance of SNGX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

SNGX long term performance overview.The bars show the price performance of SNGX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SNGX is 1.91 USD. In the past month the price decreased by -7.73%. In the past year, price decreased by -62.1%.

SOLIGENIX INC / SNGX Daily stock chart

SNGX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.08 328.06B
AMGN AMGEN INC 13.46 150.26B
GILD GILEAD SCIENCES INC 14.09 135.70B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.53B
REGN REGENERON PHARMACEUTICALS 13.61 65.13B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.83B
ARGX ARGENX SE - ADR 98.77 35.40B
ONC BEIGENE LTD-ADR 6.1 25.76B
BNTX BIONTECH SE-ADR N/A 23.69B
NTRA NATERA INC N/A 21.46B
SMMT SUMMIT THERAPEUTICS INC N/A 19.04B
BIIB BIOGEN INC 8.12 18.81B

About SNGX

Company Profile

SNGX logo image Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 14 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

Company Info

SOLIGENIX INC

29 Emmons Drive, Suite B-10

Princeton NEW JERSEY 08540 US

CEO: Christopher J. Schaber

Employees: 15

SNGX Company Website

SNGX Investor Relations

Phone: 16095388200

SOLIGENIX INC / SNGX FAQ

What is the stock price of SOLIGENIX INC today?

The current stock price of SNGX is 1.91 USD. The price increased by 5.52% in the last trading session.


What is the ticker symbol for SOLIGENIX INC stock?

The exchange symbol of SOLIGENIX INC is SNGX and it is listed on the Nasdaq exchange.


On which exchange is SNGX stock listed?

SNGX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SOLIGENIX INC stock?

7 analysts have analysed SNGX and the average price target is 22.95 USD. This implies a price increase of 1101.57% is expected in the next year compared to the current price of 1.91. Check the SOLIGENIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SOLIGENIX INC worth?

SOLIGENIX INC (SNGX) has a market capitalization of 6.23M USD. This makes SNGX a Nano Cap stock.


How many employees does SOLIGENIX INC have?

SOLIGENIX INC (SNGX) currently has 15 employees.


What are the support and resistance levels for SOLIGENIX INC (SNGX) stock?

SOLIGENIX INC (SNGX) has a support level at 1.9 and a resistance level at 1.98. Check the full technical report for a detailed analysis of SNGX support and resistance levels.


Is SOLIGENIX INC (SNGX) expected to grow?

The Revenue of SOLIGENIX INC (SNGX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the SNGX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy SOLIGENIX INC (SNGX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SOLIGENIX INC (SNGX) stock pay dividends?

SNGX does not pay a dividend.


When does SOLIGENIX INC (SNGX) report earnings?

SOLIGENIX INC (SNGX) will report earnings on 2025-08-07.


What is the Price/Earnings (PE) ratio of SOLIGENIX INC (SNGX)?

SOLIGENIX INC (SNGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.29).


What is the Short Interest ratio of SOLIGENIX INC (SNGX) stock?

The outstanding short interest for SOLIGENIX INC (SNGX) is 2.34% of its float. Check the ownership tab for more information on the SNGX short interest.


SNGX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SNGX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SNGX. SNGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SNGX Financial Highlights

Over the last trailing twelve months SNGX reported a non-GAAP Earnings per Share(EPS) of -4.29. The EPS increased by 66.06% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -92.19%
ROE -200.74%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%63.19%
Sales Q2Q%-100%
EPS 1Y (TTM)66.06%
Revenue 1Y (TTM)-85.78%

SNGX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to SNGX. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 42.41% and a revenue growth -100% for SNGX


Ownership
Inst Owners1.35%
Ins Owners0.02%
Short Float %2.34%
Short Ratio0.76
Analysts
Analysts82.86
Price Target22.95 (1101.57%)
EPS Next Y42.41%
Revenue Next Year-100%